Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner

Psychopharmacology

Volumn 233, Issue 11, 2016, Pages 2077-2097

  Holubova, Kristina ^a,b   Kleteckova, Lenka ^a,b   Skurlova, Martina ^a,b   Ricny, Jan ^b   Stuchlik, Ales ^a   Vales, Karel ^a,b  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Antidepressants; Anxiety; BDNF; Bulbectomy; Cognitive deficit; Ketamine; mTOR; Rapamycin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SODIUM CHLORIDE; ANTIDEPRESSANT AGENT; MTOR PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CAROUSEL MAZE TEST; COGNITIVE DEFECT; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; HIPPOCAMPUS; HYPERACTIVITY; MALE; MEDICAL PROCEDURES; MENTAL TASK; MORRIS WATER MAZE TEST; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PASSIVE AVOIDANCE TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANXIETY; AVOIDANCE BEHAVIOR; DRUG EFFECTS; MAZE TEST; METABOLISM; OLFACTORY BULB; PHYSIOLOGY; PSYCHOLOGY; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; AVOIDANCE LEARNING; BRAIN-DERIVED NEUROTROPHIC FACTOR; HIPPOCAMPUS; KETAMINE; MALE; MAZE LEARNING; OLFACTORY BULB; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84961825609     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4256-3     Document Type: Article

References (133)

1. Abdallah CG, Sanacora G, Duman RS, Krystal JH (2015) Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 66:509–523
2. Akana SF, Chu A, Soriano L, Dallman MF (2001) Corticosterone exerts site-specific and state-dependent effects in prefrontal cortex and amygdala on regulation of adrenocorticotropic hormone, insulin and fat depots. J Neuroendocrinol 13(7):625–637
3. Aleksandrova IY, Kuvichkin VV, Kashparov IA, Medvinskaya NI, Nesterova IV, Lunin SM, Samokhin AN, Bobkova NV (2004) Increased level of beta-amyloid in the brain of bulbectomized mice. Biochemistry (Mosc) 69(2):176–180
4. Aramburu J, Ortells MC, Tejedor S, Buxadé M, López-Rodríguez C (2014) Transcriptional regulation of the stress response by mTOR. Sci Signal 7(332):re2
5. Autry AE, Monteggia LM (2012) Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 64(2):238–258
6. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM. (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 475(7354):91–95
7. Balcells-Olivero M, Vezina P (1997) Effects of naltrexone on amphetamine-induced locomotion and rearing: acute and repeated injections. Psychopharmacology (Berlin) 131(3):230–238
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351–354
9. Bizot JC, Thiébot MH (1996) Impulsivity as a confounding factor in certain animal tests of cognitive function. Brain Res Cogn Brain Res 3(3–4):243–250
10. Blundell J, Kouser M, Powell CM (2008) Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiol Learn Mem 90(1):28–35
11. Bobkova NV, Medvinskaya NI, Kamynina AV, Aleksandrova IY, Nesterova IV, Samokhin AN, Koroev DO, Filatova MP, Nekrasov PV, Abramov AY, Leonov SV, Volpina OM (2014) Immunization with either prion protein fragment 95–123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice. Neurobiol Learn Mem 107:50–64
12. Borre Y, Sir V, de Kivit S, Westphal KG, Olivier B, Oosting RS (2012a) Minocycline restores spatial but not fear memory in olfactory bulbectomized rats. Eur J Pharmacol 697(1–3):59–64
13. Borre Y, Bosman E, Lemstra S, Westphal KG, Olivier B, Oosting RS (2012b) Memantine partly rescues behavioral and cognitive deficits in an animal model of neurodegeneration. Neuropharmacology 62(5–6):2010–2017
14. Brühl AB, Rufer M, Delsignore A, Kaffenberger T, Jäncke L, Herwig U (2011) Neural correlates of altered general emotion processing in social anxiety disorder. Brain Res 1378:72–83
15. Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11(8):1169–1180
16. Carlini VP, Machado DG, Buteler F, Ghersi M, Ponzio MF, Martini AC, Schiöth HB, de Cuneo MF, Rodrigues AL, de Barioglio SR (2012) Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice. Peptides 35(2):160–165
17. Carobrez AP, Bertoglio LJ (2005) Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29(8):1193–1205
18. Chandran A, Iyo AH, Jernigan CS, Legutko B, Austin MC, Karolewicz B (2013) Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry 40:240–245
19. Cimadevilla JM, Wesierska M, Fenton AA, Bures J (2001) Inactivating one hippocampus impairs avoidance of a stable room-defined place during dissociation of arena cues from room cues by rotation of the arena. Proc Natl Acad Sci U S A 98(6):3531–3536
20. Dawson GR, Tricklebank MD (1995) Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 16(2):33–36
21. Deli A, Schipany K, Rosner M, Höger H, Pollak A, Li L, Hengstschläger M, Lubec G (2012) Blocking mTORC1 activity by rapamycin leads to impairment of spatial memory retrieval but not acquisition in C57BL/6J mice. Behav Brain Res 229(2):320–324
22. Denk MC, Rewerts C, Holsboer F, Erhardt-Lehmann A, Turck CW (2011) Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry 168(7):751–752
23. DeRubeis RJ, Siegle GJ, Hollon SD (2008) Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci 9(10):788–796
24. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):793–802
25. Douma TN, Borre Y, Hendriksen H, Olivier B, Oosting RS (2011) Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. Psychopharmacology (Berlin) 216(4):537–544
26. Drevets WC (1999) Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 877:614–637
27. Duman RS (2014) Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci 16(1):11–27
28. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62(1):35–41
29. Dutta A, McKie S, Deakin JF (2015) Ketamine and other potential glutamate antidepressants. Psychiatry Res 225(1–2):1–13
30. Dwivedi Y, Rizavi HS, Pandey GN (2006) Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 139(3):1017–1029
31. Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN (2010) Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. Biol Psychiatry 67(11):1017–1025
32. Fernandes BS, Gama CS, Kauer-Sant’Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F (2009) Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 43(15):1200–1204
33. Fifield K, Hebert M, Williams K, Linehan V, Whiteman JD, Mac Callum P, Blundell J (2015) Time-dependent effects of rapamycin on consolidation of predator stress-induced hyperarousal. Behav Brain Res 286:104–111
34. First M, Gil-Ad I, Taler M, Tarasenko I, Novak N, Weizman A (2011) The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. J Mol Neurosci 45(2):246–255
35. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008a) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32(1):140–144
36. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008b) Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 103(6):502–506
37. Gironi Carnevale UA, Vitullo E, Sadile AG (1990) Post-trial NMDA receptor allosteric blockade differentially influences habituation of behavioral responses to novelty in the rat. Behav Brain Res 39(2):187–195
38. Granon S, Poucet B (2000) Involvement of the rat prefrontal cortex in cognitive functions: a central role for the prelimbic area. Psychobiology 28(2):229–237
39. Grønli J, Bramham C, Murison R, Kanhema T, Fiske E, Bjorvatn B, Ursin R, Portas CM (2006) Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. Pharmacol Biochem Behav 85(4):842–849
40. Groves JO (2007) Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12(12):1079–1088
41. Gustafsson G, Lira CM, Johansson J, Wisén A, Wohlfart B, Ekman R, Westrin A (2009) The acute response of plasma brain-derived neurotrophic factor as a result of exercise in major depressive disorder. Psychiatry Res 169(3):244–248
42. Hadamitzky M, Herring A, Keyvani K, Doenlen R, Krügel U, Bösche K, Orlowski K, Engler H, Schedlowski M (2014) Acute systemic rapamycin induces neurobehavioral alterations in rats. Behav Brain Res 273:16–22
43. Heinrichs SC, Koob GF (2004) Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther 311(2):427–440
44. Hellweg R, Zueger M, Fink K, Hörtnagl H, Gass P (2007) Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas. Neurobiol Dis 25(1):1–7
45. Hendriksen H, Meulendijks D, Douma TN, Bink DI, Breuer ME, Westphal KG, Olivier B, Oosting RS (2012) Environmental enrichment has antidepressant-like action without improving learning and memory deficits in olfactory bulbectomized rats. Neuropharmacology 62(1):270–277
46. Hendriksen H, Korte SM, Olivier B, Oosting RS (2015) The olfactory bulbectomy model in mice and rat: one story or two tails? Eur J Pharmacol 753:105–113
47. Herman JP (2013) Neural control of chronic stress adaptation. Front Behav Neurosci 7:61
48. Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R (2003) Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth 90(2):155–160
49. Ho YJ, Chang YC, Liu TM, Tai MY, Wong CS, Tsai YF (2000) Striatal glutamate release during novelty exposure-induced hyperactivity in olfactory bulbectomized rats. Neurosci Lett 287(2):117–120
50. Hogg S (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54(1):21–30
51. Hozumi S, Nakagawasai O, Tan-No K, Niijima F, Yamadera F, Murata A, Arai Y, Yasuhara H, Tadano T (2003) Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav Brain Res 138(1):9–15
52. Hyde LW, Gorka A, Manuck SB, Hariri AR (2011) Perceived social support moderates the link between threat-related amygdala reactivity and trait anxiety. Neuropsychologia 49(4):651–656
53. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA Jr (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37(6):1526–1533
54. Iijima M, Fukumoto K, Chaki S (2012) Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. Behav Brain Res 235(2):287–292
55. Ivanova M, Belcheva S, Belcheva I, Stoyanov Z, Tashev R (2014) Modulatory effect of VIP injected into hippocampal CA1 area on anxiety in olfactory bulbectomized rats. Acta Neurobiol Exp (Wars) 74(3):317–327
56. Jaako-Movits K, Zharkovsky A (2005) Impaired fear memory and decreased hippocampal neurogenesis following olfactory bulbectomy in rats. Eur J Neurosci 22(11):2871–2878
57. Jarosik J, Legutko B, Unsicker K, von Bohlen Und Halbach O (2007) Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp Neurol 204(1):20–28
58. Jarosik J, Legutko B, Werner S, Unsicker K, von Bohlen Und Halbach O (2011) Roles of exogenous and endogenous FGF-2 in animal models of depression. Restor Neurol Neurosci 29(3):153–165
59. Jastrzębska-Więsek M, Siwek A, Partyka A, Szewczyk B, Sowa-Kućma M, Wasik A, Kołaczkowski M, Wesołowska A (2015) Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats. Naunyn Schmiedebergs Arch Pharmacol 388(10):1079–1088
60. Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, Karolewicz B (2011) The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1774–1779
61. Jindal A, Mahesh R, Bhatt S (2015) Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: involvement of hypothalamic-pituitary-adrenal axis, cAMP signaling aspects and antioxidant defense system. Pharmacol Biochem Behav 132:20–32
62. Kamei J, Hirose N, Oka T, Miyata S, Saitoh A, Yamada M (2007) Effects of methylphenidate on the hyperemotional behavior in olfactory bulbectomized mice by using the hole-board test. J Pharmacol Sci 103(2):175–180
63. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, Malafosse A (2007) Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 61(2):240–245
64. Kelly JP, Wrynn AS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74(3):299–316
65. Kim JJ, Lee HJ, Han JS, Packard MG (2001) Amygdala is critical for stress-induced modulation of hippocampal long-term potentiation and learning. J Neurosci 21(14):5222–5228
66. Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73(12):1133–1141
67. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994):959–964
68. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69(8):754–761
69. Liu RJ, Aghajanian GK (2008) Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci U S A 105(1):359–364
70. Liu ZP, Song C, Wang M, He Y, Xu XB, Pan HQ, Chen WB, Peng WJ, Pan BX (2014) Chronic stress impairs GABAergic control of amygdala through suppressing the tonic GABAA receptor currents. Mol Brain 7:32
71. Machado DG, Cunha MP, Neis VB, Balen GO, Colla A, Grando J, Brocardo PS, Bettio LE, Capra JC, Rodrigues AL (2012a) Fluoxetine reverses depressive-like behaviors and increases hippocampal acetylcholinesterase activity induced by olfactory bulbectomy. Pharmacol Biochem Behav 103(2):220–229
72. Machado DG, Cunha MP, Neis VB, Balen GO, Colla AR, Grando J, Brocardo PS, Bettio LE, Dalmarco JB, Rial D, Prediger RD, Pizzolatti MG, Rodrigues AL (2012b) Rosmarinus officinalis L. hydroalcoholic extract, similar to fluoxetine, reverses depressive-like behavior without altering learning deficit in olfactory bulbectomized mice. J Ethnopharmacol 143(1):158–169
73. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr (2009) Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 70(12):1662–1666
74. Mar A, Spreekmeester E, Rochford J (2000) Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacology (Berlin) 150(1):52–60
75. Marsden WN (2013) Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog Neuropsychopharmacol Biol Psychiatry 43:168–184
76. McGrath C, Norman TR (1998) The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. Psychopharmacology (Berlin) 136(4):394–401
77. McGrath C, Norman TR (1999) (+)-S-20499—a potential antidepressant? A behavioural and neurochemical investigation in the olfactory bulbectomised rat. Eur Neuropsychopharmacol 9(1–2):21–27
78. McNish KA, Davis M (1997) Olfactory bulbectomy enhances sensitization of the acoustic startle reflex produced by acute or repeated stress. Behav Neurosci 111(1):80–91
79. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, Parada LF, Nestler EJ (2007) Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 61(2):187–197
80. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1):47–60
81. Mucignat-Caretta C, Bondí M, Caretta A (2004) Animal models of depression: olfactory lesions affect amygdala, subventricular zone, and aggression. Neurobiol Dis 16(2):386–395
82. Mucignat-Caretta C, Bondí M, Caretta A (2006) Time course of alterations after olfactory bulbectomy in mice. Physiol Behav 89(5):637–643
83. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503–513
84. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013a) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170(10):1134–1142
85. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74(4):250–256
86. Nakagawasai O, Hozumi S, Tan-No K, Niijima F, Arai Y, Yasuhara H, Tadano T (2003) Immunohistochemical fluorescence intensity reduction of brain somatostatin in the impairment of learning and memory-related behaviour induced by olfactory bulbectomy. Behav Brain Res 142(1–2):63–67
87. Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, Sadlik K, Piekoszewski W (2003) Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 61(2):159–164
88. Nuss P (2015) Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr Dis Treat 11:165–175
89. Opal MD, Klenotich SC, Morais M, Bessa J, Winkle J, Doukas D, Kay LJ, Sousa N, Dulawa SM (2014) Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. Mol Psychiatry 19(10):1106–1114
90. Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RD, Gudasheva TA, Samokhin AN, Seredinin SB, Noppe W, Sherstnev VV, Morozova-Roche LA (2007) The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model. J Psychopharmacol 21(6):611–619
91. Pandey DK, Rajkumar R, Mahesh R, Radha R (2008) Depressant-like effects of parthenolide in a rodent behavioural antidepressant test battery. J Pharm Pharmacol 60(12):1643–1650
92. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB (2005) Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62(3):282–288
93. Phillips ML, Drevets WC, Rauch SL, Lane R (2003) Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 54(5):515–528
94. Pochwat B, Sowa-Kucma M, Kotarska K, Misztak P, Nowak G, Szewczyk B (2015) Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway. Psychopharmacology (Berlin) 232(2):355–367
95. Polman JA, Hunter RG, Speksnijder N, van den Oever JM, Korobko OB, McEwen BS, de Kloet ER, Datson NA (2012) Glucocorticoids modulate the mTOR pathway in the hippocampus: differential effects depending on stress history. Endocrinology 153(9):4317–4327
96. Primeaux SD, Holmes PV (1999) Role of aversively motivated behavior in the olfactory bulbectomy syndrome. Physiol Behav 67(1):41–47
97. Pudell C, Vicente BA, Delattre AM, Carabelli B, Mori MA, Suchecki D, Machado RB, Zanata SM, Visentainer JV, de Oliveira Santos Junior O, Lima MM, Ferraz AC (2014) Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats. Eur J Neurosci 39(2):266–274
98. Radley JJ, Arias CM, Sawchenko PE (2006) Regional differentiation of the medial prefrontal cortex in regulating adaptive responses to acute emotional stress. J Neurosci 26(50):12967–12976
99. Rajkumar R, Pandey DK, Mahesh R, Radha R (2009) 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay. Eur J Pharmacol 608(1–3):32–41
100. Regev L, Tsoory M, Gil S, Chen A (2012) Site-specific genetic manipulation of amygdala corticotropin-releasing factor reveals its imperative role in mediating behavioral response to challenge. Biol Psychiatry 71(4):317–326
101. Rezacova L, Svoboda J, Stuchlik A, Vales K (2011) Differential effects of stable elevated levels of corticotropin-releasing hormone and systemic corticosterone on various types of rat learning. Neuro Endocrinol Lett 32(1):64–76
102. Roceri M, Hendriks W, Racagni G, Ellenbroek BA, Riva MA (2002) Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. Mol Psychiatry 7(6):609–616
103. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A (2013) Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol 28(1):87–90
104. Sajdyk TJ, Shekhar A (1997) Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res 764(1–2):262–264
105. Sanders SK, Shekhar A (1995) Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav 52(4):701–706
106. Shah SG, Klumpp H, Angstadt M, Nathan PJ, Phan KL (2009) Amygdala and insula response to emotional images in patients with generalized social anxiety disorder. J Psychiatry Neurosci 34(4):296–302
107. Shekhar A, Truitt W, Rainnie D, Sajdyk T (2005) Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety. Stress 8(4):209–219
108. Shibata S, Watanabe S (1994) Facilitatory effect of olfactory bulbectomy on 2-deoxyglucose uptake in rat amygdala slices. Brain Res 665(1):147–150
109. Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155:123–129
110. Sieck MH, Baumbach HD (1974) Differential effects of peripheral and central anosmia producing techniques on spontaneous behavior patterns. Physiol Behav 13(3):407–425
111. Song C, Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29(4–5):627–647
112. Song C, Zhang XY, Manku M (2009) Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 29(1):14–22
113. Stepanichev M, Markov D, Pasikova N, Gulyaeva N (2016) Behavior and the cholinergic parameters in olfactory bulbectomized female rodents: difference between rats and mice. Behav Brain Res 297:5–14
114. Stock HS, Hand GA, Ford K, Wilson MA (2001) Changes in defensive behaviors following olfactory bulbectomy in male and female rats. Brain Res 903(1–2):242–246
115. Stuchlik A, Rehakova L, Telensky P, Vales K (2007) Morris water maze learning in Long-Evans rats is differentially affected by blockade of D1-like and D2-like dopamine receptors. Neurosci Lett 422:169–174
116. Stuchlík A, Petrásek T, Prokopová I, Holubová K, Hatalová H, Valeš K, Kubík S, Dockery C, Wesierska M (2013) Place avoidance tasks as tools in the behavioral neuroscience of learning and memory. Physiol Res 62(Suppl 1):S1–S19
117. Swiech L, Perycz M, Malik A, Jaworski J (2008) Role of mTOR in physiology and pathology of the nervous system. Biochim Biophys Acta 1784(1):116–132
118. Szapacs ME, Mathews TA, Tessarollo L, Lyons WE, Mamounas LA, Andrews AM (2004) Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J Neurosci Methods 140:81–92
119. Takashina K, Saito H, Nishiyama N (1995) Preferential impairment of avoidance performances in amygdala-lesioned mice. Jpn J Pharmacol 67(2):107–115
120. Thiel CM, Müller CP, Huston JP, Schwarting RK (1999) High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments. Neuroscience 93(1):243–251
121. Tsai PT, Greene-Colozzi E, Goto J, Anderl S, Kwiatkowski DJ, Sahin M (2013) Prenatal rapamycin results in early and late behavioral abnormalities in wild-type C57BL/6 mice. Behav Genet 43(1):51–59
122. van der Stelt HM, Breuer ME, Olivier B, Westenberg HG (2005) Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol Psychiatry 57(9):1061–1067
123. van Rijzingen IM, Gispen WH, Spruijt BM (1995) Olfactory bulbectomy temporarily impairs Morris maze performance: an ACTH(4–9) analog accellerates return of function. Physiol Behav 58(1):147–152
124. Vertes RP (2004) Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 51(1):32–58
125. Volpina OM, Koroev DO, Volkova TD, Kamynina AV, Filatova MP, Zaporozhskaya YV, Samokhin AN, Aleksandrova IY, Bobkova NV (2015) A fragment of the receptor for advanced glycation end products restores the spatial memory of animals in a model of Alzheimer’s disease. Russ J Bioorg Chem 41(6):638–644
126. Wieronska JM, Szewczyk B, Branski P, Palucha A, Pilc A (2002) Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23(1–3):213–216
127. Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ (2005) Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 82(1):200–206
128. Yang C, Hu YM, Zhou ZQ, Zhang GF, Yang JJ (2013) Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci 118(1):3–8
129. Yoshihara Y, De Roo M, Muller D (2009) Dendritic spine formation and stabilization. Curr Opin Neurobiol 19(2):146–153
130. Yu H, Chen ZY (2011) The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol Sin 32(1):3–11
131. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856–864
132. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71(11):939–946
133. Zueger M, Urani A, Chourbaji S, Zacher C, Roche M, Harkin A, Gass P (2005) Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci Lett 374(2):142–146